nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—bone cancer	0.342	1	CbGaD
Mesalazine—MPO—Carboplatin—bone cancer	0.187	0.465	CbGbCtD
Mesalazine—MPO—Cisplatin—bone cancer	0.159	0.398	CbGbCtD
Mesalazine—PTGS2—Cisplatin—bone cancer	0.0551	0.137	CbGbCtD
Mesalazine—PPARG—periosteum—bone cancer	0.00402	0.118	CbGeAlD
Mesalazine—PPARG—leg—bone cancer	0.00321	0.0939	CbGeAlD
Mesalazine—PPARG—forelimb—bone cancer	0.00318	0.0932	CbGeAlD
Mesalazine—PPARG—hindlimb—bone cancer	0.00286	0.0838	CbGeAlD
Mesalazine—PPARG—appendage—bone cancer	0.00246	0.0719	CbGeAlD
Mesalazine—PTGS2—periosteum—bone cancer	0.00206	0.0602	CbGeAlD
Mesalazine—CHUK—connective tissue—bone cancer	0.00166	0.0485	CbGeAlD
Mesalazine—PTGS2—leg—bone cancer	0.00164	0.048	CbGeAlD
Mesalazine—PTGS2—hindlimb—bone cancer	0.00146	0.0428	CbGeAlD
Mesalazine—PTGS2—cartilage tissue—bone cancer	0.00144	0.0422	CbGeAlD
Mesalazine—PTGS2—appendage—bone cancer	0.00126	0.0368	CbGeAlD
Mesalazine—IKBKB—connective tissue—bone cancer	0.00113	0.033	CbGeAlD
Mesalazine—ALOX5—connective tissue—bone cancer	0.000934	0.0273	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—bone cancer	0.000796	0.3	CrCbGaD
Mesalazine—MPO—connective tissue—bone cancer	0.00079	0.0231	CbGeAlD
Mesalazine—IKBKB—tendon—bone cancer	0.000775	0.0227	CbGeAlD
Mesalazine—PPARG—connective tissue—bone cancer	0.000701	0.0205	CbGeAlD
Mesalazine—ALOX5—bone marrow—bone cancer	0.000622	0.0182	CbGeAlD
Mesalazine—Olsalazine—PTGS2—bone cancer	0.000546	0.206	CrCbGaD
Mesalazine—MPO—bone marrow—bone cancer	0.000526	0.0154	CbGeAlD
Mesalazine—MPO—spinal cord—bone cancer	0.000524	0.0153	CbGeAlD
Mesalazine—Aminosalicylic Acid—PTGS2—bone cancer	0.000513	0.193	CrCbGaD
Mesalazine—Diflunisal—PTGS2—bone cancer	0.000513	0.193	CrCbGaD
Mesalazine—PPARG—tendon—bone cancer	0.000482	0.0141	CbGeAlD
Mesalazine—PPARG—bone marrow—bone cancer	0.000467	0.0137	CbGeAlD
Mesalazine—PTGS1—connective tissue—bone cancer	0.000375	0.011	CbGeAlD
Mesalazine—PTGS2—connective tissue—bone cancer	0.000358	0.0105	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—bone cancer	0.000285	0.108	CrCbGaD
Mesalazine—PTGS1—tendon—bone cancer	0.000258	0.00754	CbGeAlD
Mesalazine—PTGS1—spinal cord—bone cancer	0.000249	0.00728	CbGeAlD
Mesalazine—PTGS2—tendon—bone cancer	0.000246	0.00721	CbGeAlD
Mesalazine—PTGS2—bone marrow—bone cancer	0.000239	0.00698	CbGeAlD
Mesalazine—PTGS2—spinal cord—bone cancer	0.000238	0.00695	CbGeAlD
Mesalazine—CHUK—Signaling by ERBB2—KIT—bone cancer	0.000112	0.00159	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000112	0.00159	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—JUN—bone cancer	0.000112	0.00159	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—JUN—bone cancer	0.000112	0.00159	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—KIT—bone cancer	0.000112	0.00158	CbGpPWpGaD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—EGFR—bone cancer	0.000112	0.00158	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—JUN—bone cancer	0.000111	0.00157	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—RB1—bone cancer	0.00011	0.00156	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00011	0.00156	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—JUN—bone cancer	0.00011	0.00156	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—JUN—bone cancer	0.00011	0.00156	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	0.00011	0.00156	CbGpPWpGaD
Mesalazine—Urethral disorder—Methotrexate—bone cancer	0.00011	0.000732	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—bone cancer	0.000109	0.000731	CcSEcCtD
Mesalazine—Sinusitis—Epirubicin—bone cancer	0.000109	0.00073	CcSEcCtD
Mesalazine—Agranulocytosis—Epirubicin—bone cancer	0.000109	0.000727	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—bone cancer	0.000108	0.000725	CcSEcCtD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—JUN—bone cancer	0.000108	0.00153	CbGpPWpGaD
Mesalazine—Infestation—Doxorubicin—bone cancer	0.000108	0.00072	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—bone cancer	0.000108	0.00072	CcSEcCtD
Mesalazine—PPARG—Circadian rythm related genes—CDK4—bone cancer	0.000108	0.00152	CbGpPWpGaD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000107	0.000714	CcSEcCtD
Mesalazine—PPARG—Gene Expression—FUS—bone cancer	0.000107	0.00151	CbGpPWpGaD
Mesalazine—Hypersensitivity—Cisplatin—bone cancer	0.000107	0.000712	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—BRAF—bone cancer	0.000106	0.0015	CbGpPWpGaD
Mesalazine—Renal failure—Doxorubicin—bone cancer	0.000106	0.000708	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—bone cancer	0.000106	0.000706	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000106	0.000706	CcSEcCtD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—JUN—bone cancer	0.000106	0.0015	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—KIT—bone cancer	0.000105	0.00149	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	0.000105	0.00149	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—KIT—bone cancer	0.000105	0.00149	CbGpPWpGaD
Mesalazine—Haemoglobin—Epirubicin—bone cancer	0.000105	0.000702	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000105	0.00149	CbGpPWpGaD
Mesalazine—Stomatitis—Doxorubicin—bone cancer	0.000105	0.000702	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—bone cancer	0.000105	0.000702	CcSEcCtD
Mesalazine—Rhinitis—Epirubicin—bone cancer	0.000105	0.000701	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—bone cancer	0.000105	0.0007	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—bone cancer	0.000105	0.0007	CcSEcCtD
Mesalazine—Hepatitis—Epirubicin—bone cancer	0.000105	0.000699	CcSEcCtD
Mesalazine—Haemorrhage—Epirubicin—bone cancer	0.000105	0.000699	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—bone cancer	0.000105	0.000698	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—bone cancer	0.000104	0.000696	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—KIT—bone cancer	0.000104	0.00148	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000104	0.00148	CbGpPWpGaD
Mesalazine—IKBKB—MyD88-independent cascade—JUN—bone cancer	0.000104	0.00147	CbGpPWpGaD
Mesalazine—Asthenia—Cisplatin—bone cancer	0.000104	0.000694	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—bone cancer	0.000104	0.000694	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—bone cancer	0.000104	0.000693	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—bone cancer	0.000103	0.000691	CcSEcCtD
Mesalazine—CHUK—Rac1/Pak1/p38/MMP-2 pathway—TP53—bone cancer	0.000103	0.00146	CbGpPWpGaD
Mesalazine—Urinary tract disorder—Epirubicin—bone cancer	0.000103	0.00069	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR in Cancer—KIT—bone cancer	0.000103	0.00146	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—JUN—bone cancer	0.000103	0.00146	CbGpPWpGaD
Mesalazine—Oedema peripheral—Epirubicin—bone cancer	0.000103	0.000689	CcSEcCtD
Mesalazine—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000103	0.00146	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—KIT—bone cancer	0.000103	0.00146	CbGpPWpGaD
Mesalazine—Haematuria—Doxorubicin—bone cancer	0.000103	0.000687	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—bone cancer	0.000103	0.000687	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—bone cancer	0.000103	0.000685	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000102	0.000681	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—bone cancer	0.000102	0.000679	CcSEcCtD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—JUN—bone cancer	0.000101	0.00144	CbGpPWpGaD
Mesalazine—Angiopathy—Methotrexate—bone cancer	0.000101	0.000678	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—bone cancer	0.000101	0.000676	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—bone cancer	0.000101	0.000675	CcSEcCtD
Mesalazine—CHUK—p75(NTR)-mediated signaling—TP53—bone cancer	0.000101	0.00143	CbGpPWpGaD
Mesalazine—CHUK—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bone cancer	0.000101	0.00143	CbGpPWpGaD
Mesalazine—Mediastinal disorder—Methotrexate—bone cancer	0.000101	0.000673	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—bone cancer	0.000101	0.000672	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.0001	0.00142	CbGpPWpGaD
Mesalazine—Chills—Methotrexate—bone cancer	0.0001	0.00067	CcSEcCtD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	9.99e-05	0.00142	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—MDM2—bone cancer	9.94e-05	0.00141	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.91e-05	0.0014	CbGpPWpGaD
Mesalazine—Diarrhoea—Cisplatin—bone cancer	9.91e-05	0.000662	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—bone cancer	9.89e-05	0.000661	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR in disease—BRAF—bone cancer	9.89e-05	0.0014	CbGpPWpGaD
Mesalazine—Alopecia—Methotrexate—bone cancer	9.88e-05	0.00066	CcSEcCtD
Mesalazine—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.86e-05	0.0014	CbGpPWpGaD
Mesalazine—Mental disorder—Methotrexate—bone cancer	9.8e-05	0.000654	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—bone cancer	9.78e-05	0.000653	CcSEcCtD
Mesalazine—PPARG—Metabolism—NT5C3A—bone cancer	9.76e-05	0.00138	CbGpPWpGaD
Mesalazine—Tinnitus—Epirubicin—bone cancer	9.76e-05	0.000652	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—KIT—bone cancer	9.74e-05	0.00138	CbGpPWpGaD
Mesalazine—Erythema—Methotrexate—bone cancer	9.73e-05	0.00065	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—bone cancer	9.73e-05	0.00065	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—bone cancer	9.71e-05	0.000649	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—bone cancer	9.71e-05	0.000648	CcSEcCtD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—JUN—bone cancer	9.7e-05	0.00137	CbGpPWpGaD
Mesalazine—Hepatitis—Doxorubicin—bone cancer	9.68e-05	0.000647	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—bone cancer	9.68e-05	0.000647	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—bone cancer	9.61e-05	0.000642	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—bone cancer	9.56e-05	0.000639	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—bone cancer	9.54e-05	0.000637	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	9.54e-05	0.00135	CbGpPWpGaD
Mesalazine—Dysgeusia—Methotrexate—bone cancer	9.53e-05	0.000637	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—bone cancer	9.52e-05	0.000635	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—MDM2—bone cancer	9.51e-05	0.00135	CbGpPWpGaD
Mesalazine—Angiopathy—Epirubicin—bone cancer	9.49e-05	0.000634	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—bone cancer	9.49e-05	0.000634	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—bone cancer	9.45e-05	0.000631	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—bone cancer	9.43e-05	0.00063	CcSEcCtD
Mesalazine—Back pain—Methotrexate—bone cancer	9.42e-05	0.000629	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—MDM2—bone cancer	9.41e-05	0.00133	CbGpPWpGaD
Mesalazine—Chills—Epirubicin—bone cancer	9.39e-05	0.000627	CcSEcCtD
Mesalazine—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TP53—bone cancer	9.38e-05	0.00133	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—MDM2—bone cancer	9.36e-05	0.00133	CbGpPWpGaD
Mesalazine—IKBKB—Activated TLR4 signalling—JUN—bone cancer	9.35e-05	0.00132	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—BRAF—bone cancer	9.35e-05	0.00132	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	9.32e-05	0.00132	CbGpPWpGaD
Mesalazine—Alopecia—Epirubicin—bone cancer	9.25e-05	0.000618	CcSEcCtD
Mesalazine—Vomiting—Cisplatin—bone cancer	9.2e-05	0.000615	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—bone cancer	9.17e-05	0.000613	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—bone cancer	9.17e-05	0.000612	CcSEcCtD
Mesalazine—IKBKB—p75(NTR)-mediated signaling—TP53—bone cancer	9.16e-05	0.0013	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—CDK4—bone cancer	9.16e-05	0.0013	CbGpPWpGaD
Mesalazine—Erythema multiforme—Doxorubicin—bone cancer	9.16e-05	0.000611	CcSEcCtD
Mesalazine—Rash—Cisplatin—bone cancer	9.13e-05	0.00061	CcSEcCtD
Mesalazine—Dermatitis—Cisplatin—bone cancer	9.12e-05	0.000609	CcSEcCtD
Mesalazine—Erythema—Epirubicin—bone cancer	9.11e-05	0.000608	CcSEcCtD
Mesalazine—CHUK—PI-3K cascade—EGFR—bone cancer	9.09e-05	0.00129	CbGpPWpGaD
Mesalazine—Eye disorder—Doxorubicin—bone cancer	9.05e-05	0.000604	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—bone cancer	9.03e-05	0.000603	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—bone cancer	9.03e-05	0.000603	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—bone cancer	9e-05	0.000601	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—bone cancer	8.99e-05	0.0006	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—bone cancer	8.98e-05	0.0006	CcSEcCtD
Mesalazine—Tension—Epirubicin—bone cancer	8.94e-05	0.000597	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—MDM2—bone cancer	8.94e-05	0.00127	CbGpPWpGaD
Mesalazine—Dysgeusia—Epirubicin—bone cancer	8.92e-05	0.000596	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—MDM2—bone cancer	8.89e-05	0.00126	CbGpPWpGaD
Mesalazine—CHUK—PI3K/AKT activation—EGFR—bone cancer	8.87e-05	0.00126	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—MDM2—bone cancer	8.85e-05	0.00125	CbGpPWpGaD
Mesalazine—Nervousness—Epirubicin—bone cancer	8.85e-05	0.000591	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—KIT—bone cancer	8.83e-05	0.00125	CbGpPWpGaD
Mesalazine—Back pain—Epirubicin—bone cancer	8.81e-05	0.000589	CcSEcCtD
Mesalazine—CHUK—DAP12 signaling—MDM2—bone cancer	8.81e-05	0.00125	CbGpPWpGaD
Mesalazine—CHUK—GAB1 signalosome—EGFR—bone cancer	8.8e-05	0.00125	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—JUN—bone cancer	8.79e-05	0.00125	CbGpPWpGaD
Mesalazine—Angiopathy—Doxorubicin—bone cancer	8.78e-05	0.000587	CcSEcCtD
Mesalazine—Malaise—Methotrexate—bone cancer	8.78e-05	0.000586	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—bone cancer	8.76e-05	0.000585	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	8.76e-05	0.00124	CbGpPWpGaD
Mesalazine—Immune system disorder—Doxorubicin—bone cancer	8.75e-05	0.000584	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—bone cancer	8.75e-05	0.000584	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	8.74e-05	0.00124	CbGpPWpGaD
Mesalazine—Mediastinal disorder—Doxorubicin—bone cancer	8.73e-05	0.000583	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—bone cancer	8.71e-05	0.000582	CcSEcCtD
Mesalazine—Chills—Doxorubicin—bone cancer	8.69e-05	0.00058	CcSEcCtD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	8.68e-05	0.00123	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—JUN—bone cancer	8.64e-05	0.00122	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—TP53—bone cancer	8.63e-05	0.00122	CbGpPWpGaD
Mesalazine—Nausea—Cisplatin—bone cancer	8.6e-05	0.000574	CcSEcCtD
Mesalazine—CHUK—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	8.6e-05	0.00122	CbGpPWpGaD
Mesalazine—Vision blurred—Epirubicin—bone cancer	8.59e-05	0.000573	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—bone cancer	8.56e-05	0.000571	CcSEcCtD
Mesalazine—Cough—Methotrexate—bone cancer	8.49e-05	0.000567	CcSEcCtD
Mesalazine—CHUK—BDNF signaling pathway—JUN—bone cancer	8.49e-05	0.0012	CbGpPWpGaD
Mesalazine—Mental disorder—Doxorubicin—bone cancer	8.48e-05	0.000567	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—bone cancer	8.45e-05	0.000565	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—bone cancer	8.43e-05	0.000563	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—bone cancer	8.42e-05	0.000562	CcSEcCtD
Mesalazine—CHUK—Signaling by SCF-KIT—MMP9—bone cancer	8.4e-05	0.00119	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.4e-05	0.00119	CbGpPWpGaD
Mesalazine—Flatulence—Doxorubicin—bone cancer	8.31e-05	0.000555	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—bone cancer	8.29e-05	0.000553	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—bone cancer	8.29e-05	0.000553	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—bone cancer	8.29e-05	0.000553	CcSEcCtD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	8.28e-05	0.00117	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—MDM2—bone cancer	8.28e-05	0.00117	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—MDM2—bone cancer	8.28e-05	0.00117	CbGpPWpGaD
Mesalazine—Tension—Doxorubicin—bone cancer	8.27e-05	0.000552	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—bone cancer	8.25e-05	0.000551	CcSEcCtD
Mesalazine—PTGS1—Metabolism—NDUFA12—bone cancer	8.25e-05	0.00117	CbGpPWpGaD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	8.23e-05	0.00055	CcSEcCtD
Mesalazine—Malaise—Epirubicin—bone cancer	8.22e-05	0.000549	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—MDM2—bone cancer	8.21e-05	0.00116	CbGpPWpGaD
Mesalazine—Discomfort—Methotrexate—bone cancer	8.19e-05	0.000547	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—bone cancer	8.19e-05	0.000547	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—bone cancer	8.18e-05	0.000547	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—JUN—bone cancer	8.18e-05	0.00116	CbGpPWpGaD
Mesalazine—Syncope—Epirubicin—bone cancer	8.17e-05	0.000546	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—bone cancer	8.15e-05	0.000545	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—bone cancer	8.15e-05	0.000545	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR in Cancer—MDM2—bone cancer	8.14e-05	0.00115	CbGpPWpGaD
Mesalazine—Muscle spasms—Doxorubicin—bone cancer	8.1e-05	0.000541	CcSEcCtD
Mesalazine—CHUK—Signaling by PDGF—MDM2—bone cancer	8.1e-05	0.00115	CbGpPWpGaD
Mesalazine—Palpitations—Epirubicin—bone cancer	8.05e-05	0.000538	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—bone cancer	8.01e-05	0.000535	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—bone cancer	8.01e-05	0.000535	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—RB1—bone cancer	7.96e-05	0.00113	CbGpPWpGaD
Mesalazine—Cough—Epirubicin—bone cancer	7.95e-05	0.000531	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—bone cancer	7.94e-05	0.000531	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—bone cancer	7.94e-05	0.000531	CcSEcCtD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	7.92e-05	0.00112	CbGpPWpGaD
Mesalazine—Infection—Methotrexate—bone cancer	7.89e-05	0.000527	CcSEcCtD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	7.87e-05	0.00111	CbGpPWpGaD
Mesalazine—Hypertension—Epirubicin—bone cancer	7.86e-05	0.000525	CcSEcCtD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—JUN—bone cancer	7.83e-05	0.00111	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—TP53—bone cancer	7.82e-05	0.00111	CbGpPWpGaD
Mesalazine—Ill-defined disorder—Doxorubicin—bone cancer	7.82e-05	0.000522	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	7.8e-05	0.0011	CbGpPWpGaD
Mesalazine—Nervous system disorder—Methotrexate—bone cancer	7.79e-05	0.00052	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—bone cancer	7.79e-05	0.00052	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—bone cancer	7.78e-05	0.00052	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—bone cancer	7.76e-05	0.000518	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—bone cancer	7.76e-05	0.000518	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—bone cancer	7.76e-05	0.000518	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—bone cancer	7.73e-05	0.000516	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—bone cancer	7.72e-05	0.000515	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	7.7e-05	0.000514	CcSEcCtD
Mesalazine—IKBKB—BDNF signaling pathway—JUN—bone cancer	7.7e-05	0.00109	CbGpPWpGaD
Mesalazine—Hyperhidrosis—Methotrexate—bone cancer	7.68e-05	0.000513	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—MDM2—bone cancer	7.67e-05	0.00109	CbGpPWpGaD
Mesalazine—Discomfort—Epirubicin—bone cancer	7.66e-05	0.000512	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—bone cancer	7.6e-05	0.000508	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—bone cancer	7.58e-05	0.000507	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—bone cancer	7.57e-05	0.000506	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—bone cancer	7.57e-05	0.000506	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—bone cancer	7.56e-05	0.000505	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—bone cancer	7.54e-05	0.000504	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	7.51e-05	0.00106	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	7.51e-05	0.00106	CbGpPWpGaD
Mesalazine—Confusional state—Epirubicin—bone cancer	7.5e-05	0.000501	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—bone cancer	7.45e-05	0.000497	CcSEcCtD
Mesalazine—Oedema—Epirubicin—bone cancer	7.43e-05	0.000497	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—bone cancer	7.43e-05	0.000497	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—bone cancer	7.42e-05	0.000496	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—bone cancer	7.41e-05	0.000495	CcSEcCtD
Mesalazine—PPARG—Gene Expression—NR1I2—bone cancer	7.4e-05	0.00105	CbGpPWpGaD
Mesalazine—Infection—Epirubicin—bone cancer	7.39e-05	0.000493	CcSEcCtD
Mesalazine—Cough—Doxorubicin—bone cancer	7.36e-05	0.000491	CcSEcCtD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—TP53—bone cancer	7.34e-05	0.00104	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	7.34e-05	0.00104	CbGpPWpGaD
Mesalazine—Shock—Epirubicin—bone cancer	7.31e-05	0.000489	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—bone cancer	7.29e-05	0.000487	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—bone cancer	7.28e-05	0.000486	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—bone cancer	7.28e-05	0.000486	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—bone cancer	7.26e-05	0.000485	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—bone cancer	7.24e-05	0.000483	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—bone cancer	7.22e-05	0.000482	CcSEcCtD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	7.2e-05	0.00102	CbGpPWpGaD
Mesalazine—Hyperhidrosis—Epirubicin—bone cancer	7.19e-05	0.00048	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—bone cancer	7.19e-05	0.00048	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—ATF1—bone cancer	7.18e-05	0.00102	CbGpPWpGaD
Mesalazine—Myalgia—Doxorubicin—bone cancer	7.18e-05	0.000479	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—bone cancer	7.18e-05	0.000479	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—bone cancer	7.18e-05	0.000479	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—KIT—bone cancer	7.17e-05	0.00102	CbGpPWpGaD
Mesalazine—Anxiety—Doxorubicin—bone cancer	7.15e-05	0.000478	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—bone cancer	7.13e-05	0.000476	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	7.13e-05	0.000476	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—bone cancer	7.09e-05	0.000474	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—bone cancer	7.09e-05	0.000473	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—bone cancer	7.08e-05	0.000473	CcSEcCtD
Mesalazine—IKBKB—Insulin Signaling—JUN—bone cancer	7.08e-05	0.001	CbGpPWpGaD
Mesalazine—Somnolence—Methotrexate—bone cancer	7.06e-05	0.000472	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—bone cancer	7.02e-05	0.000469	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—bone cancer	6.99e-05	0.000467	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—MDM2—bone cancer	6.95e-05	0.000985	CbGpPWpGaD
Mesalazine—Hypotension—Epirubicin—bone cancer	6.95e-05	0.000464	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—bone cancer	6.94e-05	0.000463	CcSEcCtD
Mesalazine—PPARG—Circadian rythm related genes—JUN—bone cancer	6.93e-05	0.000981	CbGpPWpGaD
Mesalazine—Decreased appetite—Methotrexate—bone cancer	6.91e-05	0.000461	CcSEcCtD
Mesalazine—ALOX5—Metabolism—ENO2—bone cancer	6.9e-05	0.000978	CbGpPWpGaD
Mesalazine—Anaphylactic shock—Doxorubicin—bone cancer	6.88e-05	0.000459	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—bone cancer	6.88e-05	0.000459	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—bone cancer	6.86e-05	0.000458	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—bone cancer	6.85e-05	0.000457	CcSEcCtD
Mesalazine—PTGS1—Metabolism—NT5C3A—bone cancer	6.84e-05	0.000968	CbGpPWpGaD
Mesalazine—Infection—Doxorubicin—bone cancer	6.83e-05	0.000456	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—JUN—bone cancer	6.81e-05	0.000964	CbGpPWpGaD
Mesalazine—Pain—Methotrexate—bone cancer	6.79e-05	0.000454	CcSEcCtD
Mesalazine—CHUK—Signaling by SCF-KIT—EGFR—bone cancer	6.79e-05	0.000962	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	6.78e-05	0.00096	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Epirubicin—bone cancer	6.77e-05	0.000452	CcSEcCtD
Mesalazine—Shock—Doxorubicin—bone cancer	6.77e-05	0.000452	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—bone cancer	6.75e-05	0.000451	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—BRAF—bone cancer	6.74e-05	0.000954	CbGpPWpGaD
Mesalazine—Thrombocytopenia—Doxorubicin—bone cancer	6.74e-05	0.00045	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—bone cancer	6.72e-05	0.000449	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—bone cancer	6.71e-05	0.000448	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—bone cancer	6.68e-05	0.000446	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—bone cancer	6.68e-05	0.000446	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—bone cancer	6.65e-05	0.000444	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—bone cancer	6.63e-05	0.000443	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—bone cancer	6.61e-05	0.000441	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—bone cancer	6.56e-05	0.000438	CcSEcCtD
Mesalazine—PTGS2—Metabolism—NDUFA12—bone cancer	6.55e-05	0.000928	CbGpPWpGaD
Mesalazine—Feeling abnormal—Methotrexate—bone cancer	6.55e-05	0.000437	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—bone cancer	6.54e-05	0.000437	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	6.53e-05	0.000925	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ATF1—bone cancer	6.51e-05	0.000922	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KIT—bone cancer	6.5e-05	0.00092	CbGpPWpGaD
Mesalazine—CHUK—Downstream signaling of activated FGFR—EGFR—bone cancer	6.5e-05	0.00092	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Methotrexate—bone cancer	6.5e-05	0.000434	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—bone cancer	6.46e-05	0.000432	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—EGFR—bone cancer	6.43e-05	0.000911	CbGpPWpGaD
Mesalazine—Hypotension—Doxorubicin—bone cancer	6.43e-05	0.000429	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—bone cancer	6.42e-05	0.000429	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—bone cancer	6.41e-05	0.000428	CcSEcCtD
Mesalazine—ALOX5—Metabolism—DHFR—bone cancer	6.41e-05	0.000907	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB4—EGFR—bone cancer	6.39e-05	0.000906	CbGpPWpGaD
Mesalazine—Constipation—Epirubicin—bone cancer	6.36e-05	0.000425	CcSEcCtD
Mesalazine—Pain—Epirubicin—bone cancer	6.36e-05	0.000425	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—bone cancer	6.31e-05	0.000422	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—bone cancer	6.28e-05	0.000419	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—bone cancer	6.28e-05	0.000419	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—bone cancer	6.27e-05	0.000419	CcSEcCtD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.23e-05	0.000882	CbGpPWpGaD
Mesalazine—Insomnia—Doxorubicin—bone cancer	6.22e-05	0.000416	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—bone cancer	6.18e-05	0.000413	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—bone cancer	6.13e-05	0.00041	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—bone cancer	6.13e-05	0.000409	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—bone cancer	6.12e-05	0.000408	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—BRAF—bone cancer	6.11e-05	0.000865	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—EGFR—bone cancer	6.11e-05	0.000865	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Epirubicin—bone cancer	6.08e-05	0.000406	CcSEcCtD
Mesalazine—CHUK—Signaling by FGFR—EGFR—bone cancer	6.08e-05	0.000861	CbGpPWpGaD
Mesalazine—Dyspepsia—Doxorubicin—bone cancer	6.06e-05	0.000404	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB2—EGFR—bone cancer	6.05e-05	0.000857	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—EGFR—bone cancer	6.02e-05	0.000852	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—GNA11—bone cancer	5.99e-05	0.000848	CbGpPWpGaD
Mesalazine—Decreased appetite—Doxorubicin—bone cancer	5.98e-05	0.000399	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—bone cancer	5.94e-05	0.000397	CcSEcCtD
Mesalazine—CHUK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	5.93e-05	0.00084	CbGpPWpGaD
Mesalazine—Fatigue—Doxorubicin—bone cancer	5.93e-05	0.000396	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—bone cancer	5.91e-05	0.000394	CcSEcCtD
Mesalazine—Pain—Doxorubicin—bone cancer	5.88e-05	0.000393	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—bone cancer	5.88e-05	0.000393	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—bone cancer	5.88e-05	0.000393	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—bone cancer	5.88e-05	0.000393	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—bone cancer	5.85e-05	0.000391	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—MMP9—bone cancer	5.74e-05	0.000813	CbGpPWpGaD
Mesalazine—Asthenia—Methotrexate—bone cancer	5.7e-05	0.000381	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—bone cancer	5.67e-05	0.000379	CcSEcCtD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	5.66e-05	0.000802	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—EGFR—bone cancer	5.66e-05	0.000802	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—EGFR—bone cancer	5.66e-05	0.000802	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—MDM2—bone cancer	5.64e-05	0.000799	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Doxorubicin—bone cancer	5.63e-05	0.000376	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—bone cancer	5.62e-05	0.000375	CcSEcCtD
Mesalazine—CHUK—Signaling by EGFR—EGFR—bone cancer	5.61e-05	0.000795	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—EGFR—bone cancer	5.56e-05	0.000788	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—EGFR—bone cancer	5.54e-05	0.000784	CbGpPWpGaD
Mesalazine—Hypersensitivity—Epirubicin—bone cancer	5.48e-05	0.000366	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—bone cancer	5.46e-05	0.000365	CcSEcCtD
Mesalazine—PPARG—Gene Expression—EIF2S1—bone cancer	5.46e-05	0.000774	CbGpPWpGaD
Mesalazine—Body temperature increased—Doxorubicin—bone cancer	5.44e-05	0.000363	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—bone cancer	5.44e-05	0.000363	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—bone cancer	5.44e-05	0.000363	CcSEcCtD
Mesalazine—ALOX5—Metabolism—CYP3A4—bone cancer	5.43e-05	0.000769	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NT5C3A—bone cancer	5.43e-05	0.000769	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.4e-05	0.000765	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—bone cancer	5.4e-05	0.000765	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	5.38e-05	0.000762	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—EGFR—bone cancer	5.35e-05	0.000758	CbGpPWpGaD
Mesalazine—Asthenia—Epirubicin—bone cancer	5.33e-05	0.000356	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.33e-05	0.000755	CbGpPWpGaD
Mesalazine—Pruritus—Epirubicin—bone cancer	5.26e-05	0.000351	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—bone cancer	5.25e-05	0.000351	CcSEcCtD
Mesalazine—CHUK—B Cell Activation—EGFR—bone cancer	5.24e-05	0.000742	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—CDK4—bone cancer	5.24e-05	0.000742	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MET—bone cancer	5.24e-05	0.000742	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GRM4—bone cancer	5.21e-05	0.000737	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RGS1—bone cancer	5.21e-05	0.000737	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	5.13e-05	0.000727	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—MDM2—bone cancer	5.12e-05	0.000725	CbGpPWpGaD
Mesalazine—Diarrhoea—Epirubicin—bone cancer	5.09e-05	0.00034	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—bone cancer	5.07e-05	0.000338	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—bone cancer	5.05e-05	0.000337	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	5.01e-05	0.00071	CbGpPWpGaD
Mesalazine—Rash—Methotrexate—bone cancer	5.01e-05	0.000335	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—bone cancer	5e-05	0.000334	CcSEcCtD
Mesalazine—Headache—Methotrexate—bone cancer	4.98e-05	0.000332	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—bone cancer	4.94e-05	0.00033	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—bone cancer	4.92e-05	0.000328	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—bone cancer	4.87e-05	0.000325	CcSEcCtD
Mesalazine—CHUK—Disease—ENO2—bone cancer	4.79e-05	0.000679	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—EGFR—bone cancer	4.75e-05	0.000673	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—EZH2—bone cancer	4.74e-05	0.000672	CbGpPWpGaD
Mesalazine—Vomiting—Epirubicin—bone cancer	4.73e-05	0.000316	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—GRM4—bone cancer	4.72e-05	0.000669	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RGS1—bone cancer	4.72e-05	0.000669	CbGpPWpGaD
Mesalazine—Nausea—Methotrexate—bone cancer	4.72e-05	0.000315	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—bone cancer	4.71e-05	0.000314	CcSEcCtD
Mesalazine—Rash—Epirubicin—bone cancer	4.69e-05	0.000313	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—bone cancer	4.68e-05	0.000313	CcSEcCtD
Mesalazine—Headache—Epirubicin—bone cancer	4.66e-05	0.000311	CcSEcCtD
Mesalazine—ALOX5—Metabolism—GSTP1—bone cancer	4.64e-05	0.000658	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—EGFR—bone cancer	4.64e-05	0.000657	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.62e-05	0.000654	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TP53—bone cancer	4.57e-05	0.000648	CbGpPWpGaD
Mesalazine—Dizziness—Doxorubicin—bone cancer	4.55e-05	0.000304	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—GRM1—bone cancer	4.51e-05	0.000639	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—bone cancer	4.49e-05	0.000637	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.47e-05	0.000634	CbGpPWpGaD
Mesalazine—CHUK—Disease—DHFR—bone cancer	4.44e-05	0.00063	CbGpPWpGaD
Mesalazine—Nausea—Epirubicin—bone cancer	4.42e-05	0.000295	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—bone cancer	4.37e-05	0.000292	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—MMP2—bone cancer	4.37e-05	0.000619	CbGpPWpGaD
Mesalazine—Rash—Doxorubicin—bone cancer	4.34e-05	0.00029	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—bone cancer	4.33e-05	0.000289	CcSEcCtD
Mesalazine—Headache—Doxorubicin—bone cancer	4.31e-05	0.000288	CcSEcCtD
Mesalazine—PPARG—Metabolism—ENO2—bone cancer	4.27e-05	0.000605	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ATF1—bone cancer	4.18e-05	0.000592	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GRM1—bone cancer	4.09e-05	0.00058	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KIT—bone cancer	4.09e-05	0.000579	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—bone cancer	4.09e-05	0.000273	CcSEcCtD
Mesalazine—CHUK—Immune System—IL3—bone cancer	4.08e-05	0.000578	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.01e-05	0.000568	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—DHFR—bone cancer	3.97e-05	0.000562	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KIT—bone cancer	3.92e-05	0.000556	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—bone cancer	3.89e-05	0.000552	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—EGFR—bone cancer	3.86e-05	0.000546	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ATF1—bone cancer	3.79e-05	0.000537	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KIT—bone cancer	3.71e-05	0.000525	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GNA11—bone cancer	3.71e-05	0.000525	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL3—bone cancer	3.7e-05	0.000524	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KIT—bone cancer	3.56e-05	0.000504	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—bone cancer	3.5e-05	0.000495	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CYP3A4—bone cancer	3.36e-05	0.000476	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.34e-05	0.000473	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MMP9—bone cancer	3.28e-05	0.000465	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFBR2—bone cancer	3.22e-05	0.000456	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MDM2—bone cancer	3.22e-05	0.000456	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SMO—bone cancer	3.18e-05	0.000451	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.16e-05	0.000447	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—MDM2—bone cancer	3.09e-05	0.000438	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO2—bone cancer	2.99e-05	0.000424	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MDM2—bone cancer	2.92e-05	0.000413	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GNA11—bone cancer	2.91e-05	0.000412	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SMO—bone cancer	2.88e-05	0.000409	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTP1—bone cancer	2.87e-05	0.000407	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO2—bone cancer	2.84e-05	0.000402	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—MDM2—bone cancer	2.8e-05	0.000397	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—JUN—bone cancer	2.8e-05	0.000396	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—DHFR—bone cancer	2.78e-05	0.000393	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ATF1—bone cancer	2.7e-05	0.000383	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—bone cancer	2.65e-05	0.000376	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.65e-05	0.000375	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNA11—bone cancer	2.64e-05	0.000374	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL3—bone cancer	2.64e-05	0.000374	CbGpPWpGaD
Mesalazine—PTGS2—Disease—DHFR—bone cancer	2.63e-05	0.000373	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNA11—bone cancer	2.6e-05	0.000368	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—JUN—bone cancer	2.54e-05	0.000359	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ATF1—bone cancer	2.45e-05	0.000347	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—bone cancer	2.4e-05	0.000341	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL3—bone cancer	2.39e-05	0.000339	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KIT—bone cancer	2.38e-05	0.000337	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO2—bone cancer	2.38e-05	0.000337	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP3A4—bone cancer	2.35e-05	0.000333	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.34e-05	0.000332	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFBR2—bone cancer	2.26e-05	0.000319	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—DHFR—bone cancer	2.2e-05	0.000312	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—bone cancer	2.2e-05	0.000312	CbGpPWpGaD
Mesalazine—CHUK—Disease—KIT—bone cancer	2.2e-05	0.000311	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KIT—bone cancer	2.16e-05	0.000306	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1R—bone cancer	2.12e-05	0.000301	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—bone cancer	2.11e-05	0.000299	CbGpPWpGaD
Mesalazine—CHUK—Disease—BRAF—bone cancer	2.07e-05	0.000293	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNA11—bone cancer	2.06e-05	0.000292	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFBR2—bone cancer	2.05e-05	0.00029	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTP1—bone cancer	2.01e-05	0.000285	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—bone cancer	1.99e-05	0.000283	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1R—bone cancer	1.92e-05	0.000273	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—bone cancer	1.92e-05	0.000271	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFBR2—bone cancer	1.91e-05	0.00027	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MDM2—bone cancer	1.87e-05	0.000266	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP3A4—bone cancer	1.87e-05	0.000265	CbGpPWpGaD
Mesalazine—CHUK—Disease—MDM2—bone cancer	1.73e-05	0.000245	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—bone cancer	1.7e-05	0.000241	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—bone cancer	1.67e-05	0.000236	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—bone cancer	1.63e-05	0.000231	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—bone cancer	1.6e-05	0.000226	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—bone cancer	1.54e-05	0.000218	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—bone cancer	1.49e-05	0.000211	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—bone cancer	1.48e-05	0.000209	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—bone cancer	1.45e-05	0.000205	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—bone cancer	1.4e-05	0.000198	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—bone cancer	1.31e-05	0.000186	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—bone cancer	1.3e-05	0.000184	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—bone cancer	1.28e-05	0.000181	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—bone cancer	1.22e-05	0.000173	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—bone cancer	1.21e-05	0.000172	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—bone cancer	1.18e-05	0.000168	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—bone cancer	1.16e-05	0.000165	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—bone cancer	1.1e-05	0.000156	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—bone cancer	1.05e-05	0.000149	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—bone cancer	1.04e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—bone cancer	1.03e-05	0.000145	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—bone cancer	1.03e-05	0.000145	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—bone cancer	9.55e-06	0.000135	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—bone cancer	9.29e-06	0.000132	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—bone cancer	8.28e-06	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—bone cancer	7.51e-06	0.000106	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—bone cancer	7.01e-06	9.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—bone cancer	6.96e-06	9.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—bone cancer	6.31e-06	8.93e-05	CbGpPWpGaD
